Haem.io

Intelligent Diagnostics for Precision Haematology

Haem.io

Intelligent Diagnostics for Precision Haematology

The Problem

Haematology diagnosis is too slow and too complex

Days to Weeks

Current diagnosis time

200+

Blood cancer subtypes

60+

Genetic markers to integrate

Unstructured Data

Genetics, cytogenetics, flow cytometry, morphology, and clinical context arrive in fragmented formats.

→

Overwhelmed Clinician

A specialist has to reconcile every source before diagnostic reasoning can even begin.

→

Complex Guidelines

WHO 2022 and ICC 2022 contain hundreds of interconnected pathways that are hard to apply consistently.

This is not just workflow friction. In acute blood cancers, time changes outcomes.

The Solution

LLM feature extraction plus formal diagnostic algorithms

Haem.io is the reasoning layer that turns fragmented diagnostic reports into a traceable clinical decision.

An LLM extracts genetic and clinical features. Haem.io's deterministic algorithms use those features for diagnosis, risk stratification, and clinical-trial matching.

~2 minutes · Explainable · Clinician-in-the-loop

Input

PDFs, scans, text reports, genomics, flow cytometry, morphology, and clinical context.

Extraction

An LLM extracts mutations, fusions, cytogenetics, flow markers, morphology, and clinical features.

Algorithms

Structured features are passed into Haem.io algorithms for diagnosis, risk, and trial matching.

Output

Diagnosis, derivation trace, risk stratification, treatment context, and eligible trials.

Product Proof

Production beta, simplified workflow, auditable output

Current status

Production beta with 10 haematologists

AML and MDS classifiers are built and being tested before formal NHS pilot validation.

Product proof

LLM extraction: unstructured reports become structured genetic and clinical features.
Diagnostic algorithms: extracted features feed diagnosis, risk, and trial matching.
Full trace: every output can be reviewed and challenged by the clinician.
Trials layer: leukemia trial matching engine built for UK studies.

Haematology Is The Wedge

Genomics-based diagnosis starts in blood cancer, then expands

Blood cancer is the first wedge for a broader genomics diagnosis platform.

The same architecture can extract molecular features, apply disease-specific algorithms, and connect patients to the next clinical action.

Now

AML / MDS

Production beta in testing with 10 haematologists.

Near term

Leukemia trials

UK trial matching engine built from patient genetics and diagnosis.

Prototype

Lung cancer

Genomics-driven solid tumour diagnosis prototype already built.

Expansion

More diseases

Further cancers first, then other genomics-led diseases over time.

Commercial signal: discussions with four interested pharma companies about grant funding linked to patient identification and trial matching.

Business Model + Market

Bottom-up NHS licensing with strategic pull from labs and pharma

Annual SaaS licensing

NHS Trusts

£50k-£100k/year

Private Hospitals

£75k-£150k/year

Diagnostic Labs

£100k-£200k/year

Why hospitals buy:Pricing is comparable to current HODS diagnostic-service spend, but HODS is an information-sharing platform with no diagnostic insight. Multiple trusts have told us they want to replace it.

1.2M

blood cancer diagnoses per year globally

200+

subtypes requiring specialist interpretation

Positioning:Most competitors focus upstream on morphology or lab automation. Those tools still need a downstream reasoning layer to turn results into meaningful hospital decisions.

Commercial extension:The same patient-identification layer supports pharma-sponsored trial matching without compromising clinical neutrality.

Clinical Validation

Endorsed by leading NHS haematologists

"Haem.io has the potential to transform diagnosis and decision making for patients with haematological malignancies across the NHS."

Prof Charles Craddock CBEChair, UK AML Research Network

"Haem.io has the potential to revolutionise the quality of care that patients receive."

Dr John ChadwickThe Christie NHS Foundation Trust

"A real step forward in what technology can offer in supporting clinicians to make accurate clinical diagnoses."

Dr Tom CoatsRoyal Devon & Exeter NHS Trust

"I would wholeheartedly recommend this platform. This will be of significant use for clinicians in the front line."

Dr P A CahalinBlackpool Teaching Hospitals NHS Trust

Buy-in from key opinion leaders in UK haematology

The Team

Founder-market fit across AI, haematology, and NHS diagnostics

Robert Lee

CEO & Co-Founder

Computer science and financial technology background, with experience at Coinbase, LSEG, and FlexTrade. Works across product development, software, regulatory planning, and research coordination.

Dr. Daniel Clarke

CTO & Co-Founder

PhD Physics, University of Manchester and CERN. Former UK Civil Service statistician. Leads cloud architecture, AI strategy, and secure data systems.

Dr. John Burthem

Chief Medical Officer & Co-Founder

FRCP, FRCPath. Senior NHS consultant at Manchester Foundation Trust, regional diagnostic service lead, 50+ publications, and UK NEQAS digital advisory lead.

Dr. Luke Carter-Brzezinski

Clinical Director & Co-Founder

Consultant Haematologist at MFT's Regional Diagnostic Service. Leads clinical outreach, validation strategy, and real-world workflow feedback from practicing clinicians.

Clinical logic co-developed directly with specialist NHS haematologists and translated into auditable software.

The Ask

£750k seed round. 18 months to Series A.

£750,000

Seed Investment | 18-Month Runway

Team

CEO & Lead Engineer£165k

Compliance Officer£105k

CMO part-time (John)£60k

Clinical Director part-time (Luke)£50k

Commercial/Sales support£40k

£420k

Regulatory & Pilots

Class I registration & compliance£40k

4 NHS pilot studies£80k

£120k

Operations

Cloud, AI compute, legal, insurance£90k

Contingency buffer£120k

£210k

Months 1-6

Complete Class I registration. Launch first 2 NHS pilot studies.

Months 6-12

Complete pilot validations. First paying customers.

Months 12-18

5+ NHS trust contracts. Series A ready.

Series A unlock: regulatory registration + NHS validation + first paid contracts = a repeatable commercial platform for haematology and genomic oncology.

Haem.io

Precision diagnostics for every haematologist, everywhere.
Built by clinicians. LLM-assisted extraction. Algorithmic by design.

Global standards. Production beta. Ready for NHS validation.

Raising £750,000 to transform haematology diagnosis

robert.lee@haem.iohaem.io